GlassScriptPhysician profile
Daniel T Flood
NPI 1649537358
$5,133.80
in general payments reported to CMS, 2019-2025
21 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $259 · 2023: $764 · 2024: $2,031 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,576 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,576.05 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,577.25 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $522.32 | 2023-2025 | Sotyktu |
| Incyte Corporation | $483.44 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $371.52 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $355.93 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $287.73 | 2023-2025 | Ilumya |
| Pfizer INC. | $257.28 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.78 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $158.20 | 2024-2025 | Taltz, Ebglyss |
| Janssen Scientific Affairs, LLC | $144.94 | 2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $130.91 | 2022-2025 | |
| Almirall LLC | $122.48 | 2023-2025 | Seysara, Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $109.65 | 2022 | |
| Ucb, INC. | $82.58 | 2024 | Bimzelx |
| Amgen INC. | $60.31 | 2024-2025 | Otezla, Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $58.35 | 2025 | Nemluvio |
| Organon LLC | $57.00 | 2025 | Vtama |
| Botanix Sb INC | $52.27 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $41.54 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $33.88 | 2024-2025 | Zoryve |
| Genzyme Corporation | $29.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.